4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Other Accumulated Expenses data on file, last reported at $200000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 24.22% year-over-year to $200000.0 in Q1 2026; TTM through Mar 2026 was $200000.0, a 24.22% increase from a year earlier, with the FY2025 full-year figure at $129000.0, up 13.16% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $200000.0, up from $129000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for FDMT reached as high as $748000.0 in Q2 2022 and fell as low as $45000.0 in Q1 2023.
• Historically, Other Accumulated Expenses has averaged $180411.8 across 5 years, with a median of $129000.0 in 2025.
• Across the five-year window, Other Accumulated Expenses plunged 93.18% in 2023 and surged 215.56% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $382000.0 in 2022, then tumbled by 72.77% to $104000.0 in 2023, then increased by 9.62% to $114000.0 in 2024, then grew by 13.16% to $129000.0 in 2025, then jumped by 55.04% to $200000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $200000.0 in Q1 2026, $129000.0 in Q4 2025, and $108000.0 in Q3 2025.